These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17952006

  • 1. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H, Shirouzu K.
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ.
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [Abstract] [Full Text] [Related]

  • 3. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.
    Hepatogastroenterology; 2008 Dec; 55(86-87):1631-5. PubMed ID: 19102357
    [Abstract] [Full Text] [Related]

  • 4. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D.
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [Abstract] [Full Text] [Related]

  • 5. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H, Nishiike S, Yamamoto Y, Takenaka Y, Nakahara S, Yasui T, Hanamoto A, Inohara H.
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [Abstract] [Full Text] [Related]

  • 6. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [Abstract] [Full Text] [Related]

  • 7. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [Abstract] [Full Text] [Related]

  • 8. Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study.
    Laack E, Andritzky B, Dürk H, Burkholder I, Edler L, Schuch G, Boeters I, Görn M, Lipp R, Horst H, Popp J, Hossfeld DK.
    Onkologie; 2005 Dec; 28(12):647-50. PubMed ID: 16330888
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [Abstract] [Full Text] [Related]

  • 10. A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer.
    Fahlke J, Ridwelski K, Schmidt C, Hribaschek K, Stuebs P, Kettner E, Quietzsch D, Assmann M, Deist T, Keilholz U, Lippert H.
    Chemotherapy; 2007 Jul; 53(6):454-60. PubMed ID: 17957099
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Jul; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 12. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
    Honda M, Miura A, Izumi Y, Kato T, Ryotokuji T, Monma K, Fujiwara J, Egashira H, Nemoto T.
    Dis Esophagus; 2010 Nov; 23(8):641-5. PubMed ID: 20545978
    [Abstract] [Full Text] [Related]

  • 13. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
    Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, Ryoo HM, Baek JH, Song HS.
    Cancer Chemother Pharmacol; 2010 May; 66(1):31-6. PubMed ID: 19763571
    [Abstract] [Full Text] [Related]

  • 14. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT, Uncu D, Ozdemir N, Budakoglu B, Odabaş H, Abali H, Oksuzoglu B, Aksoy S, Zengin N.
    Chemotherapy; 2011 May; 57(3):230-5. PubMed ID: 21597287
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.
    Kim H, Park JH, Bang SJ, Kim DH, Cho HR, Kim GY, Min YJ.
    Jpn J Clin Oncol; 2005 Dec; 35(12):727-32. PubMed ID: 16332720
    [Abstract] [Full Text] [Related]

  • 16. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
    Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M, Doki Y.
    Oncology; 2011 Dec; 80(5-6):307-13. PubMed ID: 21778771
    [Abstract] [Full Text] [Related]

  • 17. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY, Cho JY, Paik YH, Lee DK, Lee SI, Park HJ, Lee SJ, Lee KS, Yoon DS, Choi SH.
    Oncology; 2007 Dec; 73(1-2):2-8. PubMed ID: 18332648
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
    Oh DY, Kim TY, Kwon JH, Lee JJ, Joh Y, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK.
    Jpn J Clin Oncol; 2005 Jul; 35(7):380-5. PubMed ID: 15976069
    [Abstract] [Full Text] [Related]

  • 19. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.